Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -39.60% | -5.65% | 6.16% | 4.50% | 44.14% |
| Total Depreciation and Amortization | 27.59% | 45.83% | 70.00% | 55.80% | 61.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.59% | -26.05% | -34.24% | -55.95% | 152.96% |
| Change in Net Operating Assets | 67.16% | -39.32% | -191.16% | -61.09% | -173.93% |
| Cash from Operations | 10.55% | -31.45% | -12.91% | -30.89% | 13.76% |
| Capital Expenditure | 28.36% | 100.00% | -- | -- | -91.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 449.34% | 10.63% | -639.38% | 360.60% | 93.22% |
| Cash from Investing | 411.42% | 13.03% | -644.42% | 357.65% | 92.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 100.00% | -- |
| Foreign Exchange rate Adjustments | -260.53% | 78.95% | -317.39% | 800.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.35% | -23.32% | 11.41% | 34.62% | 27.79% |